Envíos recientes

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

Lee, Jung-Yun; Makker, Vicky; OAKNIN, ANA; OH, DO-YOUN; Banerjee, Susana; González Martín , Antonio (Fecha de publicación: 2024-10-29)

Advanced/metastatic solid tumors; HER2 testing; Trastuzumab deruxtecan

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures

Galson, Jacob D.; Schaetzle, Sebastian; Bashford-Rogers, Rachael; Raybould, Matthew I. J.; Kovaltsuk, Aleksandr; Kilpatrick, Gavin J.; Seoane Suarez, Joan (Fecha de publicación: 2021-09-09)

Repertori de cèl·lules B; SARS-CoV-2; Anticòs

TFIIIC as a Potential Epigenetic Modulator of Histone Acetylation in Human Stem Cells

Vezzoli, Marco; De Llobet Cucalon, Lara; Di Vona, Chiara; Morselli, Marco; Montanini, Barbara; de la Luna, Susana (Fecha de publicación: 2023-03-10)

Acetylation; Neurogenesis

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

Petrelli, Annalisa; rizzolio, sabrina; Pietrantonio, Filippo; bellomo, sara erika; Benelli, Matteo; de cecco, loris; Llop-Guevara, Alba; Serra, Violeta (Fecha de publicación: 2023-07-05)

Mutations; Gastric cancers; PARP inhibitors

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

Tolaney, Sara M; Arteaga, Carlos; Cortés Castan, Javier; Rugo, Hope; Bardia, Aditya; Sohn, Joohyuk (Fecha de publicación: 2021-10-22)

HER2-negative; Metastatic breast cancer; Sacituzumab govitecan

Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma

Mellid López, Sara; Gil, Eduardo; Letón, Rocío; Honrado Franco, Emiliano; Richter, Susan; Lopez Fernandez, Adrià; Caleiras, Eduardo (Fecha de publicación: 2023-03-14)

Co-occurrent mutations; Germline mutation; Pheochromocytoma

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Ameratunga, Malaka; Braña Garcia, Irene; Bono, Petri; Postel-Vinay, Sophie; Plummer, Ruth; Aspegren, John (Fecha de publicación: 2021-10-29)

Desenvolupament de fàrmacs; Melanoma

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study

Duell, Johannes; André, Marc; GAIDANO, Gianluca; GONZALEZ BARCA, EVA; Jurczak, Wojciech; Abrisqueta, Pau (Fecha de publicación: 2024-02-12)

Tafasitamab; Diffuse large B-cell lymphoma; Relapsed

TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics

Senis Herrero, Elena; Esgleas, Miriam; Najas, Sonia; Jiménez-Sábado, Verónica; Bertani, Camilla; Gimenez Alejandre, Marta; Escriche, Alba; Jimenez, Mireia; Nuciforo, Paolo Giovanni; Abad Mendez, Maria (Fecha de publicación: 2022-02-25)

Microproteínas; Diferenciación neural; Formación de neuritas

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Naing, Aung; Papadopoulos, Kyriakos P; Pishvaian, Michael; rahma, osama; Hanna, Glenn; GARRALDA, Elena; Saavedra, Omar (Fecha de publicación: 2025-02-06)

Colorectal cancer; Immunotherapy; Solid tumour

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service

Matta, Bruna; Gomes Junior, Renan Gabriel; Mattos, Daniel; Olicio, Renata; Macedo do Nascimento, Caroline; Ferreira, Gerson Moura (Fecha de publicación: 2022-12-29)

Cancer; Genetics; Risk factors

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

Morancho Armisen, Beatriz; Román Alonso, Macarena; Ovejero Romero, Pablo; Arribas López, Joaquin Vicente; Arenas Lahuerta, Enrique Javier; Martínez-Sabadell, Alex; Rius Ruiz, Irene; Escorihuela Baez, Marta (Fecha de publicación: 2022-12-20)

Cancer; Antigen; Resistance

Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset

Ricciardi, Antonio; Prados, Ferran; Yiannakas, Marios; Solanky, Bhavana; Grussu, Francesco; Kanber, Baris (Fecha de publicación: 2023-04-27)

MRI; Machine learning; Multiple sclerosis

Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects

Gulde, Sebastian; Foscarini, Alessia; April-Monn, Simon L.; Genio, Edoardo; Marangelo, Alessandro; Satam, Swapna; Toledo, Rodrigo (Fecha de publicación: 2023-06-06)

Buparlisib; Combination therapy; Primary human tumoroids

B Cells in Breast Cancer Pathology

Li, Mengyuan; Quintana Vega, Angela; Alberts, Ellie; Hung, Miu Shing; Boulat, Victoire; Martí, Mercè; Grigoriadis, Anita (Fecha de publicación: 2023-04-25)

B cells; Breast cancer; Lymph nodes

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

Cebrià Costa, Joan Pau; Serra Bardenys, Gemma; Querol, J; Cosín, M; Verde, Gaetano; Nuciforo, Paolo Giovanni; Rodilla Benito, Verónica; Arribas López, Joaquin Vicente; Peiro Sales, Sandra; Bernadó Morales, Cristina; Pascual Reguant, Laura; Gonzalez-Perez, Abel (Fecha de publicación: 2021-11-05)

Cromosomes; Marcadors pronòstics

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Sablin, Marie-Paule; Bergh, Jonas; Lu, Yen-Shen; Martínez, Noelia; Cortés Castan, Javier; Schmid, Peter; Im, Seock-Ah (Fecha de publicación: 2021-06-29)

Càncer de mama; HER2-negatiu; Receptor hormonal positiu

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Bang, Yung-Jue; Ryu, Min-Hee; FAGNIEZ, Nathalie; Tabernero, Josep; Bedard, Philippe; Vieito , Maria (Fecha de publicación: 2023-09-04)

Advanced solid tumors; Pharmacokinetics; Antitumor activity

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

Gorbatenko, Andrej; Søkilde, Rolf; Sorensen, Ester E.; Newie, Inga; Persson, Helena; Morancho Armisen, Beatriz; Arribas López, Joaquin Vicente (Fecha de publicación: 2021-04-20)

Mecanismes de la malaltia; Càncer de mama

Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence

Cabeza-Segura, Manuel; Ferreira, Rui M.; Barros, Rita; Santos-Antunes, João; Groen - van Schooten, Tessa Suzanne; Martinez Ciarpaglini, Carolina; Ruiz Pace, Fiorella; Díez García, Marc; Alsina, Maria; Dienstmann, Rodrigo (Fecha de publicación: 2025-05-06)

Immune profiling; Gastric adenocarcinomas; Microbiome

Articles científics - VHIO: Envíos recientes

Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 ﻿

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures ﻿

TFIIIC as a Potential Epigenetic Modulator of Histone Acetylation in Human Stem Cells ﻿

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors ﻿

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer ﻿

Co-occurrence of mutations in NF1 and other susceptibility genes in pheochromocytoma and paraganglioma ﻿

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours ﻿

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study ﻿

TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics ﻿

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours ﻿

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service ﻿

The target antigen determines the mechanism of acquired resistance to T cell-based therapies ﻿

Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset ﻿

Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects ﻿

B Cells in Breast Cancer Pathology ﻿

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells ﻿

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer ﻿

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens ﻿

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 ﻿

Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence ﻿